A Greek researcher has headed a study which discovered how specifically targeted cancer treatment improved patient survival rates.
Apostolia Tsimperidou at the Anderson Cancer Centre of the University of Texas in Houston has overseen a multi-year study called IMPACT which involved 3,743 patients aged 16 to 86 years old, with various types of advanced cancer.
According to an Athens-Macedonian Agency (AMNA) report, the study found that personalized therapies that focus on specific gene mutations in each patient offered the best possible treatment.
It also confirmed that precision medicine is a more successful treatment strategy than non-targeted gene and molecular traditional therapy.
Specifically, Tsimperidou’s study showed that the average survival time of the group receiving targeted treatment was 9.3 months, as opposed to 7.3 months in patients receiving conventional treatments.
The patients surviving for up to three years reached 15 percent in the case of targeted treatment, compared with seven percent in non-targeted treatment. Ten-year survival was achieved by six percent of patients who received targeted treatment, compared with only one percent of those who did not.
The researchers presented their findings at the annual conference of the American Society of Clinical Oncology in Chicago. The Greek doctor is one of the pioneers in promoting cancer prevention, her focus being in phase I clinical trials, target therapies and cancer molecular biology.